MedTrace Logo

Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

NCT02151994 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2016-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses

Conditions

  • Hypertension and Chronic Heart Failure

Interventions

DRUG

BIA 5-1058

oral administration

DRUG

Placebo

oral administration

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02151994 on ClinicalTrials.gov